RVMD slips as investors price in $2.2B equity-and-convert financing overhang
Revolution Medicines (RVMD) is sliding as investors digest a recent upsized financing that issued new shares at $142 and $500 million of 0.50% convertible notes due 2033. With the stock still near the deal price area, trading is being shaped by dilution/convertible-overhang positioning ahead of the company’s May 6, 2026 Q1 results date.
1) What’s moving the stock today
Revolution Medicines shares are trading lower as the market continues to absorb the company’s recently closed, upsized capital raise that combined common stock issuance and convertible notes. The deal created immediate equity dilution and added a potential future share-supply overhang via conversion, which can pressure shares in the weeks following pricing—especially when the stock trades close to the offering level.
2) The financing details investors are focused on
The company closed concurrent upsized public offerings on April 17, 2026 with aggregate gross proceeds of about $2.225 billion, including 12,147,887 common shares sold at $142.00 and $500.0 million of 0.50% convertible senior notes due 2033. The notes mature May 1, 2033 and carry an initial conversion rate of 5.0302 shares per $1,000 principal (implying an initial conversion price near $198.80 per share), creating a second layer of potential dilution if the stock rallies into the conversion zone.
3) Why the timing matters (near-term calendar)
The pullback is also landing just ahead of a scheduled corporate checkpoint: Revolution Medicines has said it will report first-quarter 2026 financial results after market close on Wednesday, May 6, 2026. For pre-revenue clinical-stage oncology companies, earnings releases often function as an update on cash runway, operating expense trajectory, and trial timelines—factors that can amplify positioning once a large financing has reset the balance sheet.